Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine

References

• Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov.7, 426–437 (2008).
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev.61, 105–123 (2009).
   PubMed Web of Science ®Google Scholar
• Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol. Sci.30, 563–569 (2009).
   PubMed Web of Science ®Google Scholar
• Zarate C Jr, Machado-Viera R, Henter I, Ibrahim L, Diazgranados N, Salvadore G. Glutamatergic modulators: the future of treating mood disorders? Harv. Rev. Psychiatry18, 293–303 (2010).
   PubMed Web of Science ®Google Scholar
• Hashimoto K. The role of glutamate on the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry DOI: 10.1016/j.pnpbp.2010.06.013 (2010) (Epub ahead of print).
   Google Scholar
• Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry25, 1310–1316 (2007).
   Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry63, 856–864 (2006).
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE et al. A randomized add-on of an N-methyl-D-aspartate aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry67, 793–802 (2010).
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry DOI: 10.4088/JCP.09m05327blu (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Maeng S, Zarate CA Jr, Du J et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry63, 349–352 (2008).
   PubMed Web of Science ®Google Scholar
• Li N, Lee B, Liu RJ et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science329, 959–964 (2010).
   PubMed Web of Science ®Google Scholar
• Costa-Mattioli M, Sossin WS, Klann E, Sonenberg N. Translational control of long-lasting synaptic plasticity and memory. Neuron61, 10–26 (2009).
   PubMed Web of Science ®Google Scholar
• Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci.33, 67–75 (2009).
   PubMed Web of Science ®Google Scholar
• Cryan JF, O’Leary OF. A glutamate pathway to faster-acting antidepressants? Science329, 913–914 (2010).
   PubMed Web of Science ®Google Scholar
• Cleary C, Linde JA, Hiscock KM et al. Antidepressive-like effects of rapamycin in animal models: implications for mTOR inhibition as a new target for treatment of affective disorders. Brain Res. Bull.76, 469–473 (2008).
   PubMed Web of Science ®Google Scholar
• Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: a historical overview and future directions. Psychiatry Clin. Neurosci.64, 341–357 (2010).
   PubMed Web of Science ®Google Scholar
• Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry64, 527–532 (2008).
   PubMed Web of Science ®Google Scholar
• Molendijk ML, Bus BA, Spinhoven P et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol. Psychiatry DOI: 10.1038/mp.2010.98 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Slipczuk L, Bekinschtein P, Katche C, Cammarota M, Izquierdo I, Medina JH. BDNF activates mTOR to regulate GluR1 expression required for memory formation. PLoS One4, e6007 (2009).
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol.28, 631–637 (2008).
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. σ-1 receptor chaperons at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell131, 596–610 (2007).
   PubMed Web of Science ®Google Scholar
• Stahl SM. The σ enigma: can σ receptors provide a novel target for disorders of mood and cognition? J. Clin. Psychiatry69, 1673–1674 (2008).
   PubMed Web of Science ®Google Scholar
• Hashimoto K. σ-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent. Nerv. Syst. Agents Med. Chem.9, 197–204 (2009).
   PubMedGoogle Scholar
• Hashimoto K. Comments on “An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate anatgonist, CP-101,606, in patients with treatment-refractory major depressive disorder”. J. Clin. Psychopharmacol.29, 411–412 (2009).
   PubMed Web of Science ®Google Scholar
• Arachchige Don AS, Zheng XF. Recent clinical trials of mTOR-targeted cancer therapies. Rev. Recent Clin. Trials (2010) (Epub ahead of print).
   Google Scholar